Thai FDA Approves China’s Sinopharm Vaccine
Thailand's Food and Drug Administration (FDA) on Friday (May 28) has approved the Sinopham Covid-19 vaccine developed by Beijing Bio-Institute of Biological Products Co., Ltd.
Thailand's Food and Drug Administration (FDA) on Friday (May 28) has approved the Sinopham Covid-19 vaccine developed by Beijing Bio-Institute of Biological Products Co., Ltd.
28 พ.ค. 2564

Thailand’s Food and Drug Administration (FDA) on Friday (May 28) has approved the Sinopham Covid-19 vaccine developed by Beijing Bio-Institute of Biological Products Co., Ltd. It is recommended that the second dose should be administered 21 to 28 days after the first dose. 
China’s state-owned Sinopharm earlier got the World Health Organization (WHO) emergency approval in early-May.
Currently, FDA Thailand has authorized five Covid-19 vaccines, including the following:
1) AstraZeneca’s Covid-19 vaccine, which is developed in collaboration with Oxford University in the United Kingdom and is being manufactured locally by Siam Bioscience Co., Ltd.
2) Coronavac vaccine or Sinovac imported by the Government Pharmaceutical Organization.
3) Johnson &amp; Johnson’s Janssen Covid-19 Vaccine
4) Moderna Covid vaccine by Zuellig Pharma Ltd.
5) Sinopham Covid-19 vaccine developed by Biogenetech Co., Ltd.
The other two vaccines; Sputnik V vaccine and Covaxin vaccine are currently in registration process to seek approval from FDA.